Searchable abstracts of presentations at key conferences in endocrinology

ea0026p328 | Obesity | ECE2011

Letrozole normalizes serum testosterone but has no clinical effects in men with obesity-related hypogonadotropic hypogonadism

Loves S , de Jong J , van Sorge A , Telting D , Hermus A , de Boer H

Introduction: Hypogonadotropic hypogonadism is frequently observed in morbidly obese men, due to aromatase-dependent conversion of androgens to estrogens. The clinical impact of this sex hormone imbalance is unknown.Aim: Evaluate the clinical effects of aromatase inhibition in obesity-related hypogonadism.Methods: Double-blind, placebo-controlled, 6-month trial in severely obese men (BMI>35 kg/m2) with obesity-relate...

ea0026p66 | Endocrine tumours and neoplasia | ECE2011

Metabolic endocrine tumor activity is reflected by total 18F-DOPA PET tumor uptake in patients with a carcinoid tumor

Fiebrich H-B , de Jong J R , Kema I P , Koopmans K P , Sluiter W J , Dierckx R A J O , Walenkamp A M E , Brouwers A H , de Vries E G E , Links T P

Introduction: Positron emission tomography (PET) using 6-[F-18]fluoro-L-dihydroxyphenylalanine (18F-DOPA) has an excellent sensitivity to detect carcinoid tumor lesions. 18F-DOPA-tumor uptake and the levels of biochemical tumor markers are mediated by tumor endocrine metabolic activity. Therefore we evaluated whether total 18F-DOPA-tumor uptake on PET, defined as the whole-body metabolic burden (WBMTB) reflects tumor load per pat...